Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W, Winter S, Büttner F, Goletz S, Faißt S, Brinkmann F, Saladores P, Heidemann E, Ott G, Gerteis A, Alscher MD, Dippon J, Schwab M, Brauch H, Fritz P. Schroth W, et al. Among authors: brauch h. Breast Cancer Res Treat. 2016 Jan;155(1):85-97. doi: 10.1007/s10549-015-3651-5. Epub 2015 Dec 9. Breast Cancer Res Treat. 2016. PMID: 26650824
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.
Jaremko M, Justenhoven C, Schroth W, Abraham BK, Fritz P, Vollmert C, Illig T, Simon W, Schwab M, Brauch H. Jaremko M, et al. Among authors: brauch h. Pharmacogenet Genomics. 2007 Jul;17(7):529-38. doi: 10.1097/FPC.0b013e32801233fc. Pharmacogenet Genomics. 2007. PMID: 17558308
Breast cancer: a candidate gene approach across the estrogen metabolic pathway.
Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H. Justenhoven C, et al. Among authors: brauch h. Breast Cancer Res Treat. 2008 Mar;108(1):137-49. doi: 10.1007/s10549-007-9586-8. Epub 2007 Jun 23. Breast Cancer Res Treat. 2008. PMID: 17588204
The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study.
Frank B, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, Reed MW, Sutter C, Wappenschmidt B, Balasubramanian SP, Meindl A, Kiechle M, Bugert P, Schmutzler RK, Bartram CR, Justenhoven C, Ko YD, Brüning T, Brauch H, Hamann U, Pharoah PP, Dunning AM, Pooley KA, Easton DF, Cox A, Burwinkel B. Frank B, et al. Among authors: brauch h. Breast Cancer Res Treat. 2008 Sep;111(1):139-44. doi: 10.1007/s10549-007-9752-z. Epub 2007 Sep 21. Breast Cancer Res Treat. 2008. PMID: 17891485
The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.
Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Brüning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H. Justenhoven C, et al. Among authors: brauch h. Breast Cancer Res Treat. 2008 Sep;111(1):171-7. doi: 10.1007/s10549-007-9762-x. Epub 2007 Oct 6. Breast Cancer Res Treat. 2008. PMID: 17922187
341 results